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ABSTRACT 
Schizophrenia is a chronic, disabling disorder, which 
commonly emerges in adolescence and young adulthood. 
While pharmacological treatment with currently avail-
able second-generation antipsychotics exerts beneficial 
effects on the positive symptoms of schizophrenia, they 
have little effect on negative symptoms or cognitive defi-
cits. Because these two types of symptoms are enduring, 
and negatively impact social functioning throughout 
the course of the illness, there is an urgent requirement 
to develop new effective therapeutic approaches to 
manage them. Negative symptoms have proven difficult 
to assess accurately because of their complexity, even 
with commonly used clinical rating scales such as the 
Scales for Assessment of Negative Symptoms (SANS). 
In this context, new “next-generation” assessment tools 
have recently been developed, which include items 
representing the five domains encompassed by the two 
established clusters of negative symptoms (diminished 
expression and avolition), and enable the detection 
of changes in severity. Despite various therapeutic 
approaches to alleviating negative symptoms, there are 
currently no established methods available for clinical 
practice. Cognitive deficits are also a core feature in the 
majority of people with schizophrenia, with impaired 
performance observed across many cognitive domains, 
including verbal memory, working memory, attention, 
and executive functions. Such cognitive deficits are like-
ly associated with either reduced or inefficient function 
of related distributed neural networks. Psychosocial 
treatments for cognitive impairments in schizophrenia 
seem promising given the beneficial effects of cognitive 
remediation therapy on such impairments, as well as 
on social functioning, as substantiated in several meta-
analytic studies with modest effect sizes. Furthermore, 
using functional neuroimaging techniques, the size of 
these therapy-induced beneficial changes in neurocogni-
tive performance has been demonstrated to be correlated 
with the degree of the changes in brain activation during 
performing some cognitive tasks in the prefrontal and 
temporal cortices. This suggests neurobiological effects 
are exerted by psychosocial cognitive remediation treat-
ments.
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Schizophrenia is a chronic, debilitating psychiatric 
disorder that usually manifests with frank psychotic 
symptoms, such as auditory hallucinations and delusions 
of persecution, which are referred to as positive symp-
toms. Negative symptoms, including low motivation and 
diminished verbal and/or non-verbal expression, and 
cognitive dysfunction may precede the emergence of 
these positive symptoms. However, they tend to attract 
less attention, and generally persist as residual symptoms 
following treatment. 
 Schizophrenia has an incidence of at least 0.7% of 
the population, and the age of onset generally ranges 
from adolescence to early adulthood, indicating that it 
represents a persistent burden for those with the disorder. 
Pharmacological treatment with currently available 
antipsychotic drugs is moderately to greatly effective in 
the relief of acute positive symptoms and for maintenance 
of stabilization. Nonetheless, the other two major classes 
of symptoms (i.e., negative and cognitive symptoms) are 
much less responsive to pharmacotherapy in both the first 
episode of psychosis1, 2 and in chronic schizophrenia.3 In 
addition, these two problems have been demonstrated 
to have a detrimental impact on social functioning and 
quality of life in people with schizophrenia.4, 5 Thus, it is 
important to elucidate the pathophysiology underlying 
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these two classes of symptoms in schizophrenia, and to 
develop effective and tolerable treatment methods. 
 This review aims to provide a brief overview of 
current literature regarding negative symptoms and cog-
nitive impairment in schizophrenia. We focus mainly on 
the clinical concepts and promising recovery-oriented 
treatment methods that specifically target these two 
classes of symptoms.
NEGATIVE SYMPTOMS
Phenomenology
From a clinical point of view, people with schizophrenia 
likely exhibit both primary and secondary negative 
symptoms. While primary negative symptoms are 
part of the disease process itself, secondary negative 
symptoms, by definition, develop as a result of factors 
such as drug-induced extra-pyramidal side effects, social 
withdrawal due to suspicious delusions, depression, 
environmental deprivation, and anticipated stigma.6, 7 
Therefore, secondary and primary negative symptoms 
should be differentiated to determine the true severity of 
primary negative symptoms.
 Although the general concept of primary negative 
symptoms is well accepted as a core domain of schizo-
phrenia, its components were not adequately identified 
until recently despite considerable efforts.8 Studies 
using factor analysis have been used to develop a con-
struct for primary negative symptoms, and consistently 
suggest two distinct clusters comprising five domains 
(Table 1).9, 10 These include: a) a cluster of diminished 
verbal and/or non-verbal expression (blunted affect and 
poverty of speech); and b) a cluster of avolition, i.e., 
reduced motivation and pleasure (amotivation, anhedo-
nia, and asociality). There is a prevailing consensus for 
this conceptualization including five domains.8, 9 
 Negative symptoms can be accurately separated 
from the other major characteristic symptoms of schizo-
phrenia (i.e., positive symptoms, disorganized thoughts 
and behavior, depression, and cognitive impairment).9 
This suggests that negative symptoms are likely related 
to different underlying pathophysiology to that under-
lying positive symptoms. As such, they are likely to be 
responsive to treatments other than pharmacotherapy 
with current antipsychotics. Indeed, second-generation 
antipsychotic medications do not adequately alleviate 
negative symptoms, which means early high hopes 
for these drugs have faded.1 To develop new effective 
therapeutic approaches specifically targeting negative 
symptoms, an evidence-based rating instrument should 
be developed that can measure both the severity of each 
construct dimension and their change over time.11 
Table 1. Two main clusters and five domains of nega-
tive symptoms
Cluster and domain Domain characteristics 
A. Diminished expression Reduced behaviors related to the expression of emotion
1. Blunted affect
Reduced intensity and range of emo-
tional expression shown in verbal or 
non-verbal modes of communication
2. Alogia Reduced quantity of speech and loss of conversation fluency
B. Avolition Loss of behaviors, interests, motiva-tion, and desires 
1. Amotivation Deficits in the initiation and mainte-nance of goal-oriented behaviors
2. Anhedonia Impaired anticipation of reward
3. Asociality Diminished interest in social interac-tions with others
Assessment
It is important to bear in mind that most rating scales for 
negative symptoms necessarily require, at least in part, 
inferences from the patient’s self-report of avolition, 
which requires rating subjective feelings. These infer-
ences are probably limited by communication abilities, 
and an individual may have inherent difficulties in rating 
their own negative symptoms. 
 The Scale for Assessment of Negative symptoms 
(SANS: 25 items, covering the five subdomains of 
affective flattening, alogia, avolition/apathy, anhedonia/
asociality, and attention),12 and the Positive and Negative 
Syndrome Scale (PANSS) negative subscale items (7 
items, covering blunted affect, emotional withdrawal, 
poor rapport, passive social withdrawal, difficulty in ab-
stract thinking, lack of spontaneity and flow of conver-
sation, and stereotyped thinking)13 are commonly used 
to assess negative symptoms in schizophrenia. Although 
these two scales have been shown to be reliable and 
valid rating tools for measuring negative symptoms, 
some fundamental problems arise from the fact that 
they do not necessarily include the whole range of true 
negative symptoms, or that they may incorporate symp-
toms that are not currently considered as true negative 
symptoms. For example, the PANSS negative subscales 
fail to fully cover the whole range of negative symp-
toms.10 Moreover, the SANS and PANSS both includes 
subscales for attentional deficits, which are more likely 
to belong to disorganization syndrome than negative 
symptoms.10 In addition, these scales are less sensitive to 
rapid changes in the severity of negative symptoms over 
longer observation periods of more than a month.10 
 To minimize these weaknesses, and to facilitate 
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development of effective treatment approaches for neg-
ative symptoms in schizophrenia, the National Institute 
of Mental Health’s Consensus Development Conference 
on Negative Symptoms formed a workgroup to develop 
new instruments that should include the five agreed-upon 
subdomains and enable us to detect changes in their sever-
ity.14 As a result, two “next-generation” rating scales have 
recently  been developed for use in treatment trials and 
research on negative symptoms, with strong convergent 
and discriminant validity, test-retest reliability, and inter-
nal consistency. These are: (1) the Clinical Assessment 
Interview for Negative Symptoms (CAINS); and (2) the 
Brief Negative Symptom Scale (BNSS). 
 The 13-item CAINS has a two-factor structure, 
expression (four items) and motivation/pleasure (nine 
items), and was intended to cover each subdomain in 
extensive detail. Its ratings combine measurements 
based on individuals’ reports of subjectively experienced 
pleasure in relevant activities in the past week with 
those of anticipatory pleasure.15 Given the evidence that 
anhedonia in schizophrenia is probably anticipatory in 
nature rather than experiential,16 measuring both types 
of anhedonia may contribute to further elucidating such 
characteristics of this disorder. 
 The BNSS also has 13-item structure, and similar 
properties to the CAINS in that it assesses two types 
of anhedonia. However, the BNSS was intended to be 
concise enough to be feasible for large, multicenter trials 
and clinical use.14 The 13 items are organized into six 
subscales, and rating usually takes about 20 minutes. 
The most remarkable feature of its construct is that, 
unlike other scales for negative symptoms, it includes 
a “Distress” subscale, which measures the level of the 
absence of dysphoria, confirmed by a negative correla-
tion between the BNSS “Distress” item and a sum of the 
PANSS “Depression”, “Guilt”, “Anxiety”, and “Hostility” 
items.14 
 Both the CAINS and BNSS are becoming more 
widely used, with confirmation of their good psycho-
metric properties. A recent study comparing the two 
measures reported moderate to high correspondences 
for blunted affect, alogia, asociality, and avolition 
subdomains, but low correspondence for the anhedonia 
subdomain.17 Such a difference may arise from differ-
ences in precisely what the scales assess. For example, 
the CAINS items only assess the frequency of pleasure, 
whereas the BNSS items assess both intensity and 
frequency of pleasure. Differences may also stem from 
the characteristics of anhedonia in people with schizo-
phrenia such that they exhibit a dissociation between 
the capacity for pleasure (“liking”) and the frequency of 
seeking out rewarding activities (“wanting”). This may 
result in a low correlation between BNSS ratings of the 
intensity of past enjoyable events and CAINS ratings of 
the frequency of past pleasure. Given the reasons for the 
development of these two next-generation rating scales, 
they should be used to assess the efficacy of new treat-
ment approaches for negative symptoms.
Treatment
Recovery for people with schizophrenia should include 
a substantial improvement in negative symptoms and 
cognitive deficits, because these symptoms are found to 
be highly stable over time and have a long-lasting seri-
ous impact on functional outcomes.18 Although there has 
been extensive investigations of the efficacy of various 
therapeutic approaches to improve functioning of people 
with schizophrenia by alleviating negative symptoms, 
there are currently no well-established therapeutic meth-
ods.19–21 
 Table 2 presents efficacy as pooled standardized 
mean differences (SMDs) for several treatments for nega-
tive symptoms, which were reported in a meta-analysis of 
168 placebo-controlled trials.21 The authors of this meta-
analysis argued that such an apparent positive effect 
does not necessarily represent a clinically meaningful 
effect, because it may partly be based on improvements 
in secondary negative symptoms or there may be a lack 
of beneficial effects on functioning.21 
Table 2. Efficacy of placebo-controlled treatments for negative symptoms (modified from Fusar-Poli et al., 2015)  
Treatment N SMD 95% CI Z P
Comb 33 –0.518 –0.757 to –0.279 4.24 < .001
AD 26 –0.349 –0.551 to –0.146 3.37 .001
FGA 10 –0.531 –1.104 to 0.041 1.82 .069
SGA 38 –0.579 –0.755 to –0.404 6.47 < .001
Psych 27 –0.518 –0.757 to –0.279 4.64 < .001
Glut 26 –0.289 –0.478 to –0.1 2.99 .003
AD, antidepressant; CI, confidence interval; Comb, combined treatment; FGA, first-generation antipsychotic; Glut, glutamatergic agents; 
Psych, psychological therapy; SGA, second-generation antipsychotic; SMD, standardized mean difference; Z, z-test.
94
K. Kaneko
 As an extensive and detailed description of treat-
ment approaches for negative symptoms is not within the 
scope of this review, we briefly mention some specific 
pharmacological agents (second-generation antipsychot-
ics, antidepressants, glutamatergic medications, and psy-
chostimulants) and psychological interventions (cognitive 
behavioral therapy, CBT) in the following sections. 
Pharmacological treatments
Where certain pharmacological agents appear to exert a 
measurably beneficial effect on negative symptoms in a 
clinical trial, the results should be cautiously interpreted 
because there are many important methodological 
considerations that must be taken into account.10 These 
include the definition, assessment, and persistence of 
negative symptoms, the contribution of secondary nega-
tive symptoms, the trial duration, and so on.
Second-generation antipsychotics
Pharmacological therapy with antipsychotics is the 
mainstay in the treatment of schizophrenia.22 However, 
it is generally observed that antipsychotics exert far 
more significant effects on positive symptoms than they 
do on negative symptoms or cognitive impairment. 
Indeed, second generation antipsychotic medications 
appear not to adequately alleviate negative symptoms, 
leading to the fading of early, strongly-held hopes for 
these drugs in many countries (with the exception of 
amisulpiride).1, 19 
 A recent meta-analysis intended to clarify the 
efficacy of available treatments on negative symptoms, 
reporting a medium effect size of 0.579.21 However, such 
beneficial effects yielded by antipsychotics may possibly 
be produced by improving symptoms other than pri-
mary negative symptoms, e.g., asociality due to positive 
symptoms, suggesting that observed negative symptoms 
that show improvements are secondary in nature.   
Antidepressants
It is reasonable that depression contributes to negative 
symptoms considering the conceptual proximity of 
its clinical expression (e.g., both negative symptoms 
and depression are associated with reduced emotional 
expression and poverty of speech), and the underlying 
neural substrates.10, 23 Therefore, several classes of add-
on antidepressants have been investigated as potential 
treatments for negative symptoms. 
 Two meta-analyses have evaluated the efficacy of 
antidepressants in treating negative symptoms. In one 
study, the authors analyzed 22 publications that assessed 
symptoms with standardized rating scales, including 
the SANS total, PANSS negative, and Brief Psychiatric 
Rating Scale (BPRS).23 In the other meta-analysis, 
the authors exclusively examined studies that enrolled 
participants with pronounced negative symptoms.24 Both 
studies reported a beneficial, medium effect size, where-
as a previously mentioned meta-analysis that included 
any available treatment had reported a small effect size, 
but concluded that such small effects were not clinically 
meaningful.21 A major reason for this interpretation is 
that observed improvements in negative symptoms may 
have been partly based on improvements in secondary 
negative symptoms.21 
 Therefore, although the possible efficacy of anti-
depressants to alleviate negative symptoms appears 
encouraging, the inherent difficulty in distinguishing 
between negative symptoms and depression should be 
borne in mind.10
Glutamatergic agents
A well-established neurochemical hypothesis of the 
pathophysiology of schizophrenia suggests it results 
from N-methyl-D-aspartate (NMDA) receptor hy-
pofunction.25 This hypothesis is based on the well-
known finding that NMDA receptor antagonists, such 
as phencyclidine (PCP), can produce both positive- and 
negative-like symptoms.25 Moreover, such antagonists 
also induce neurocognitive deficits similar to those 
observed in schizophrenia across various subdomains of 
neurocognition, e.g., executive processing26 and working 
memory.27 
 Several glutamatergic agents that modulate NMDA 
receptor function, either acting directly or indirectly 
at the receptors, have been examined as possible phar-
macological treatments for negative symptoms. These 
include agonists of the glycine site of NMDA receptors 
(glycine) and the partial agonist (D-cycloserine), a 
glycine transporter-1 inhibitor (sarcosine), an uncompet-
itive NMDA receptor antagonist (memantine), and an 
anticonvulsant (lamotrigine), which inhibits glutamate 
release resulting in apparently paradoxical actions.19 
 Results of a meta-analysis in which various kinds of 
NMDA receptor modulators (including D-cycloserine, 
glycine, and sarcosine) were examined reported evi-
dence of a small effect size for these agents as a group.28 
In addition, small to medium effect sizes were observed 
specifically for D-serine and sarcosine.28 Therefore, 
agents that modulate NMDA receptor function may 
offer a promising treatment for negative symptoms, al-
though positive findings are not always consistent among 
studies.29
 
Psychostimulants
The possible therapeutic basis of psychostimulants, such 
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as amphetamine-based drugs and modafinil, in alleviat-
ing negative symptoms is that they facilitate dopaminer-
gic transmission in the prefrontal cortex (PFC), which is 
assumed to be reduced in schizophrenia.30 
 Despite the potential risks of abuse and exacerbating 
psychotic symptoms, a systematic review of psycho-
stimulant treatments for negative symptoms reported 
that amphetamine-based drugs have a relatively low risk 
of aggravating positive symptoms in patients who are 
clinically stable and adherent to antipsychotic medica-
tions. However, this evidence is limited because of small 
samples and short durations of the studies included.31 
Modafinil and its enantiomer armodafinil generally 
show only limited clinical effects for reducing negative 
symptoms, which might result from their weaker inhib-
itory actions on the dopamine transporter than amphet-
amine.32 
  
Psychosocial treatment
Current psychiatric clinical practice should promote the 
recovery of people with mental illness. The modern con-
cept of recovery stresses the importance of improving 
subjective well-being and quality of life of patients, as 
well as social functioning including independent living 
skills, and capacity to work or study.33 Both negative 
symptoms and cognitive impairments are known to del-
eteriously impact on these functions.18 Because current 
pharmacological approaches exert minimal effects on 
these symptoms, non-somatic, psychosocial interven-
tions are considered especially important in the manage-
ment of persistent, drug-resistant symptoms.34 It is now 
assumed that negative symptoms are not a consequence 
of fixed deficits but can at least partly be considered as 
dysfunctional beliefs about one’s cognitive and social 
abilities, as well as one’s aptitude for pleasure.20, 35 From 
this new viewpoint, it is possible that psychosocial treat-
ments will have beneficial effects on negative symptoms. 
 Among various kinds of psychosocial treatment ap-
proaches aimed at alleviating symptoms of schizophre-
nia, CBT appears by far to be the most established and 
frequently sought approach. Therefore, in this review, 
discussion of the efficacy of psychosocial treatments for 
negative symptoms will be confined to that of CBT. 
 CBT for schizophrenia was originally developed 
to reduce positive symptoms, with a primary focus on 
psychotic symptoms and general approaches adopted 
to weaken firm beliefs.36 This is substantially different 
from traditional CBT for mood and anxiety disorders. 
As such, very few clinical studies have addressed 
negative symptoms as a primary outcome. The liter-
ature on the therapeutic effects of CBT on positive 
symptoms appears to warrant the conclusion that such 
psychological therapy is more effective than usual treat-
ment.37, 38 Nonetheless, results from clinical trials and a 
meta-analysis of the efficacy of CBT in treating negative 
symptoms of psychosis appear to be mixed.20 
 Early clinical studies mostly tended to indicate ben-
eficial effects of CBT on negative symptoms, as reported 
in a meta-analysis by Wykes et al., in which they report-
ed an effect size of 0.44.37 However, the majority of early 
published clinical trials examining the efficacy of CBT 
for schizophrenia assessed negative symptom severity as 
a secondary outcome. In contrast, more recent meta-an-
alytic studies conducted to take into account various 
sources of bias on effect size fail to support the efficacy 
of CBT to improve symptomatic measures.20, 39 In 
these meta-analyses, effect sizes were calculated using 
Hedges’ g, the standardized difference between means, 
and reported effect sizes of CBT for negative symptoms 
were as following: In studies with negative symptoms as 
a secondary outcome, Jauhar et al.39 reported an effect 
size of 0.13 (95% confidence interval, CI, 0.01 to 0.25) 
and Velthorst et al. reported an effect size of 0.093 (95% 
CI –0.028 to 0.214) for CBT for negative symptoms. 
Similar effect size of 0.157 (95% CI –0.10 to 0.409) has 
been reported in studies that focus on negative symp-
toms as a primary outcome.20 
 Such large differences between older and newer 
studies in reported effect sizes for CBT cannot be 
attributed to difference in the demographic properties 
of participants, study samples, number of treatment 
sessions, characteristics of the control group, number 
of treatment ingredient, or illness duration.20 However, 
there appears to be three plausible reasons for the ob-
served decline in effect sizes suggested by the two recent 
meta-analytic studies mentioned above. First, various 
sources of potential bias observed in older CBT trials, 
such as insufficient masking when assessing outcome 
measures, likely have profound effects on their results 
as demonstrated by Jauhar et al.39 Second, newer studies 
more often target a single clear-cut outcome, such as 
auditory hallucinations, which might result in smaller 
improvements in negative symptom measures. Third, 
results of older behavior-oriented studies may suggest 
CBT is more effective in alleviating negative symptoms 
than more recent cognition-oriented studies. This pos-
sibility suggests the importance of individuals’ active 
participation in social activities. 
 In this context, it is especially noteworthy that a re-
cent 18-month recovery-oriented cognitive therapy trial 
targeting low-functioning people with schizophrenia 
successfully yielded clinically significant improvements 
in negative symptoms and global functioning.40 The 
therapy was intended to be flexible regarding the plans 
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and schedules based on the participant’s needs and 
progress. It was also aimed at stimulating their interest 
and motivation to focus on achievable goals based on the 
available time. 
 The efficacy of this promising cognitive therapy 
to alleviate negative symptoms suggests that these 
apparently persistent symptoms may arise at least partly 
from dysfunctional beliefs about an individual’s own 
abilities, and that they are not completely determined 
by hedonic deficits inherent to schizophrenia.20 Because 
dysfunctional beliefs have been shown to mediate the 
association between neurocognitive impairment and 
negative symptoms,40, 41 such nihilistic beliefs should 
be a target of psychological treatment to aid recovery. 
However, more research is required to draw firm conclu-
sions about the efficacy of this kind of cognitive therapy 
for persistent negative symptoms.     
COGNITIVE IMPAIRMENT 
The dominant view in the past was that people with 
schizophrenia have limited, if any, neuropsychological 
impairments resulting from psychotic symptoms. 
However, compromised neurocognition has more 
recently been established as a core feature of schizo-
phrenia.42 Cognitive impairments have been observed 
in the majority of patients with schizophrenia, but not 
all.43 It is particularly important to note that, in contrast 
to psychotic symptoms, cognitive impairment predicts a 
range of poor functional outcomes, e.g., verbal memory 
is associated with all types of functional outcome exam-
ined.44 
 From a longitudinal perspective, cognitive deficits 
are evident before florid symptoms emerge with substan-
tial cognitive impairments already present at the time 
of first psychiatric contact.45, 46 These impairments have 
been shown to persist after psychotic symptoms have re-
mitted, indicating that cognitive impairments are present 
throughout all phases of the illness, including in clinical 
high-risk cohorts,47 first episode patients,48 and patients 
with chronic schizophrenia.49 A systematic review of 
58 studies of the associations between neurocognitive 
impairments and psychotic psychopathology has docu-
mented that negative and disorganized dimensions are 
modestly associated with cognitive deficits, whereas 
positive and depressive dimensions are not.50 This sug-
gests that impaired neurocognition is not secondary to 
positive symptoms.  
Profile of neurocognitive deficits 
Generalized cognitive deficits
General neurocognitive ability has been measured in 
schizophrenia by either measuring the intelligence 
quotient (IQ) or composite scores obtained from neu-
ropsychological test batteries comprising multiple tests 
that assess different cognitive abilities. Standardized IQ 
tests primarily focus on the measurement of crystallized 
abilities,51 whereas neuropsychological test batteries 
mainly measure multiple cognitive abilities including 
verbal memory, working memory, attention, and execu-
tive functions. 
 With these measures, it has been shown that the 
illness results in a generalized impairment of cognitive 
performance across many cognitive domains, which are 
affected to a fairly similar extent. This naturally leads 
to the hypothesis that cognitive impairment inherent 
to schizophrenia appears to be global in nature. This 
hypothesis has been supported by the results of two 
large-scale meta-analytic studies.52, 53 These studies have 
reported “severe” cognitive deficits based on a Cohen’s d 
of –0.92 and –0.98.
Specific cognitive deficits
As general neuropsychological tests often do not assess 
pure domains of neurocognitive ability, the results 
yielded by such tests should be interpreted carefully. 
Despite the apparent global nature of neurocognitive 
impairments in schizophrenia, a group of experts who 
worked on the Measurement and Treatment Research 
to Improve Cognition in Schizophrenia (MATRICS) 
project proposed seven key domains of cognitive deficits 
in the condition, which are assumed to be most impaired 
and most strongly correlated with outcome. These were 
working memory, attention/vigilance, verbal learning 
and memory, visual learning and memory, reasoning 
and problem solving, speed of processing, and social 
cognition.54 In this section, brief descriptions of these 
cognitive domains are provided mainly with reference to 
Keefe and Harvey.55 
Vigilance and attention
Sources of attention can be broken down into three 
functions: alerting, orienting, and executive control.56 
Vigilance means the ability to maintain attention over 
time. People with schizophrenia can have difficulties 
in being fully engaged in everyday conversations with 
others and in following important instructions at work.42 
These cognitive deficits appear related to functional 
outcomes, such as community functioning and skills 
acquisition.42
Verbal learning and memory
To encode new information, store it over time, and 
retrieve it requires memory functions. Historically, 
memory was not regarded to be severely impaired in 
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schizophrenia. However, modern, precise, standardized 
neuropsychological measurements applied in schizo-
phrenia research have suggested severe deficits in mem-
ory ability with effect sizes of less than –1.0.42 People 
with schizophrenia generally exhibit larger impairments 
in encoding than in retrieval.42 Moreover, verbal memory 
impairments are associated with real-world functioning.
Visual learning and memory
Visual memory describes the relationship between 
visually perceived information and its encoding, storage, 
and retrieval. The degree of deficit in these abilities in 
schizophrenia is usually less than that of memory.42 This 
cognitive ability has been shown to be moderately cor-
related with employment status and strongly correlated 
with functional capacity.  
Reasoning and problem solving
Some of the most commonly used and most well-known 
cognitive tests include the Wisconsin Card Sorting Test 
(WCST) and the Stroop test. People with schizophrenia 
exhibit poor performance on both these tests. The 
WCST is generally interpreted as assessing abstraction/
problem-solving skills and the ability to efficiently shift 
between adopted strategies. However, performance on 
the task does not reflect a single measure of executive 
functions but various kinds of cognitive abilities. People 
with schizophrenia often display poor performance on 
this task, which reflects difficulties in adapting to chang-
es in the world around them.42
Speed of processing
Processing speed is defined as the speed at which 
cognitive operations can be executed and it likely af-
fects various neurocognitive processes, suggesting that 
impairments in this cognitive function are non-specific. 
Such deficits have been found to correlate with various 
measures of functioning, including daily life activities, 
job tenure, and independent living status.42 In a recent 
meta-analysis of cognitive deficits, this measure was 
reported to be the most severe impairment in schizo-
phrenia.53 
Working memory
Working memory (WM) has been often defined as 
the temporal storage and manipulation of incoming 
information to perform complex cognitive tasks.57 Due 
to remarkable correlations between WM measures and 
other neurocognitive abilities, impaired WM has been 
regarded as a core component of cognitive impairments 
in schizophrenia,58 and appears to be related to employ-
ment status and job tenure.55 Verbal or spatial working 
memory tasks conducted in a large number of functional 
magnetic resonance imaging (fMRI) studies have sug-
gested altered levels of activation in the prefrontal and 
anterior cingulate cortical regions, and posterior parietal 
cortex.59
Social cognition
Social cognition is defined as the ability to construct 
representations of the relationships between oneself and 
others, and to use those representations flexibly to guide 
social behavior, which is qualitatively distinct from 
neurocognition. Research of schizophrenia has mainly 
focused on theory of mind (making inferences about 
another’s intentions), social perception, emotional pro-
cessing, and attribution style, with reports of substantial 
impairments across these subdomains. Impaired social 
cognition is related to social impairments and is shown 
to largely mediate the effects of neurocognition on func-
tional outcome.60 
Assessment 
Assessment of neurocognitive function appears to be 
less challenging than that of negative symptoms because 
there already exist established test batteries for the as-
sessment of neurocognitive abilities, for which reliability 
and validity have been demonstrated. 
 The most well-known and most comprehensive test 
battery is the MATRICS Consensus Cognitive Battery 
(MCCB),61 which was intended to be used across 
treatment studies targeting neurocognition. This battery 
measures the above mentioned seven key domains of 
cognitive abilities with high sensitivity. 
 Another test battery that is less exhaustive than 
the MCCB and requires minimal time for completion 
and so is utilized widely in clinical studies is the Brief 
Assessment of Cognition in Schizophrenia (BACS).62 
The BACS covers six neurocognitive domains of verbal 
memory, working memory, motor speed, attention, 
executive functions, and verbal fluency. This battery 
also provides a composite score that is calculated by 
averaging all of the six standardized primary measures 
and that can reflect treatment-induced changes due to 
its high reliability.62 Compared with age- and parental 
education-matched healthy controls, people with 
schizophrenia have BACS composite scores of about 1.5 
standard deviations lower.
Treatment
The current ultimate goal of treatment for schizophrenia 
should be to facilitate recovery by improving long-term 
functioning of people with the illness beyond the remis-
sion of psychotic symptoms. Improving brain function 
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(especially activity of the PFC during cognitive load) 
can result in better functional outcomes because it has 
been reported to be closely associated with cognitive 
functioning measures even when assessed with different 
scales functions.63–65 However, there are no approved 
treatments for impaired cognition, whether pharmaco-
logical or psychological. 
 In this section, greater emphasis is given to newly 
developed cognitive remediation (CR) therapy than 
pharmacotherapy, which has shown minimal benefits.55
Second-generation antipsychotics
Although early clinical studies reported that second-
generation antipsychotics yielded greater cognitive 
benefits than did first-generation antipsychotics, results 
of later studies did not support these findings. Observed 
effect sizes were small (0.2–0.5), and this magnitude 
was viewed as consistent with practice and/or placebo 
effects.55 In addition, small cognitive benefits of second-
generation antipsychotics in first-episode patients ap-
peared to be related to symptom changes, although the 
correlation was weak.66 Therefore, the current literature 
suggests that antipsychotics provide limited benefits for 
cognition.55 
Cognitive remediation (CR) 
CR therapy for schizophrenia aims to improve cogni-
tive abilities through a wide range of learning-based 
interventions with the ultimate goal of generalization of 
cognitive skills to functional skills, as well as to other 
untrained neurocognitive tests, and enhanced real-world 
functioning.67 
 Accumulating data indicate beneficial effects of 
CR on neurocognition despite wide variability in the 
remediation approaches employed. Indeed, almost all 
meta-analyses have demonstrated moderate68, 69 to large70 
effect sizes of CR on global neurocognition. Although 
the efficacy of CR for social functioning has been found 
to be generally smaller than that for neurocognitive abil-
ities, it has also been shown to be greater when provided 
with adjunctive psychiatric rehabilitation (Cohen’s d = 
0.59) than when given alone (d = 0.28).69 Moreover, du-
rability of training effects have been repeatedly shown 
to be six months or more after training,71 which has been 
confirmed by two large-scale meta-analyses.68, 69 
 From the results of these studies, it appears that 
there exists no conclusively demonstrated moderator 
variables that affect outcomes, including methodological 
qualities (e.g., type of control group and masking), 
participant characteristics (e.g., age and severity of 
baseline symptoms), and program characteristics (e.g., 
drill and practice vs. drill and practice plus strategy 
coaching, hours of practice, and top-down vs. bottom-up 
strategies). However, a meta-analysis by Wykes et al. 
reported that among studies providing adjunctive psychi-
atric rehabilitation programs, there are more beneficial 
effects of a CR program employing strategy coaching 
than other programs only applying a drill and practice 
approach.69 In consequence, it is currently difficult to 
identify key elements of CR interventions because of 
considerable variation among CR programs with few 
studies of adequate methodological quality available to 
date.   
 Although the neural mechanisms underlying bene-
ficial CR effects on cognition and functioning currently 
remain unclear, recent functional or structural neuro-
imaging studies have reported brain changes that may 
be associated with CR effects. One systematic review 
included studies investigating both CR effects on cog-
nition and longitudinal changes in neural measures that 
would reflect either functional neural activity or brain 
structure assessed at pre-treatment and post-treatment.72 
This systematic review included seven functional mag-
netic resonance imaging (fMRI) studies, all of which 
reported possible CR effect-related brain changes. These 
were either an increase or a decrease in BOLD signals 
or functional connectivity in brain regions of people 
with schizophrenia, but regions did not necessarily 
completely overlap across the studies. These putative 
“CR effect-related” brain regions include prefrontal, 
temporal, parietal, occipital, and limbic areas, with the 
PFC being the most consistently reported region.72 
 One near-infrared spectroscopic study with a longi-
tudinal design also reported putative CR-related changes 
in WM task-elicited brain activation in the right pre-
frontal and temporal cortices, the magnitude of which 
was correlated with improvements in neurocognitive 
measures of verbal memory and verbal fluency (Fig. 1).73 
In addition, structural changes possibly due to CR have 
also been observed in two reviewed studies, including 
neuroprotective effects associated with increased amyg-
dala volume,74 and increased white matter integrity of 
the genu and body of the corpus callosum, which was 
negatively associated with the degree of normalization 
of heightened task-related functional connectivity.75 
 A meta-analysis of nine CR studies examining 
changes in functional activation with fMRI or positron 
emission tomography investigated with an activation 
likelihood estimation (ALE) method investigated wheth-
er CR delivered via variable methods could cause plastic 
changes in common neuroanatomical regions or not.76 
ALE analyses comparing brain activation at two time 
points (pre- and post-training) revealed increased activi-
ty in the lateral and medial PFC, parietal cortex, insula, 
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Fig. 1. The extent of improvements in performance of some neurocognitive functions following cognitive remediation (CR) are signifi -
cantly correlated with the magnitude of increases in working memory task-elicited prefrontal and temporal hemodynamic responses 
during working memory task measured with near-infrared spectroscopy (NIRS).
(A) The relationship between cognitive function and changes in the concentration of oxy-hemoglobin ([oxy-Hb]) associated with working 
memory tasks before and after cognitive remediation. Red circles with the channel number in white indicate the locations of channels and, 
measurement points for 52-channel NIRS. Green and yellow represent the channels in which there are verbal memory and verbal fl uency 
changes, respectively, in the Japanese version of the Brief Assessment of Cognition in Schizophrenia (BACS-J). 
(B) Scatter diagrams showing the relationship between verbal memory and [oxy-Hb] changes in channel 33 (Spearman’s Rho; rho = 0.497, 
P = 0.030). 
(C) Scatter diagrams showing the relationship between verbal fl uency and [oxy-Hb] change in channel 36 (rho = 0.563, P = 0.015). The 
locations of near-infrared spectroscopy channels were probabilistically estimated and anatomically labeled in the standard brain space.
and the caudate and thalamus. It is particularly note-
worthy that CR-related, activated regions in the left PFC 
and thalamus partially overlap with previously identifi ed 
areas associated with defi cits in WM, executive control, 
and facial emotion processing in schizophrenia (Fig. 2).76 
This fi nding may indicate that CR employing variable 
training methods elicits neural plasticity in brain areas 
that underlie cognitive processes. Therefore, it is possi-
ble that CR can improve cognition and functioning by 
enhancing both neuroplasticity in these brain regions 
and motivation for recovery. 
 Nonetheless, considerable efforts are required to de-
velop feasible treatment methods that support recovery 
of people with schizophrenia, and that particularly target 
the two persistent and distressing symptoms of negative 
symptoms and cognitive defi cits.
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Figure 2	
Fig. 2. Cognitive remediation (CR)-elicited changes in brain activation showing that CR training supports restorative functioning in pre-
frontal and thalamic areas (with permission of Oxford University Press provided February 19, 2018) 
(A) Increased CR-elicited functional activation in the left prefrontal cortex overlaps with areas shown to have dysfunctional processing in 
previous cognition and affective processing activation likelihood estimation (ALE) meta-analyses. 
(B) Increased CR-elicited functional activation in the thalamus and caudate nucleus overlaps with an area showing defi cits in affective 
processing and is adjacent to a thalamic area showing defi cits in working memory (WM) ALE. 
Note: Areas in red depict brain regions that exhibited signifi cant CR-elicited changes in the current ALE. Blue areas depict previously 
published results comparing healthy controls (HC) > patients with schizophrenia (SZ) on tasks measuring working memory (WM) and 
executive functioning. Green areas depict previously published results comparing HC > SZ on tasks measuring affective processing. 
Purple indicates overlap between CR and the WM ALE, and yellow indicates overlap between CR and the affective processing ALE. 
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